Cumberland Pharmaceuticals will recall six lots of Acetadote injection because of a particulate matter observed in a "very small" number of 30 mL single-dose glass vials, according to a Cumberland news release.
Acetadote is used in the emergency department and administered intravenously within 8-10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen to prevent or lessen hepatic injury. Acetadote is the only injectable product approved in the U.S. to treat acetaminophen overdose.
Read the Cumberland Pharmaceuticals report on Acetadote.
Read more on supply chain issues:
-Study: Few Health Advocacy Groups Disclose Funding From Drug Makers
-Medline Launches Orthopedic Soft Goods Line
-New Device Manufacturer Tax Could Increase Medical Device Outsourcing
Acetadote is used in the emergency department and administered intravenously within 8-10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen to prevent or lessen hepatic injury. Acetadote is the only injectable product approved in the U.S. to treat acetaminophen overdose.
Read the Cumberland Pharmaceuticals report on Acetadote.
Read more on supply chain issues:
-Study: Few Health Advocacy Groups Disclose Funding From Drug Makers
-Medline Launches Orthopedic Soft Goods Line
-New Device Manufacturer Tax Could Increase Medical Device Outsourcing